Ohr Pharmaceutical shares plummet after eye drug fails in wet-AMD trial

This article was originally published here

Shares in Ohr Pharmaceutical (NSDQ:OHRP) dropped -83% to trade at 35¢ apiece this morning after the company revealed that its topical therapy did not meet the primary endpoint of a trial evaluating its efficacy as a treatment for wet age-related macular degeneration.

The company’s Mako study randomized patients 1:1 to receive either Ohr’s topical, twice-daily squalamine therapy in combination with monthly Lucentis injections or a placebo combined with Lucentis.

Get the full story at our sister site, Drug Delivery Business News.

The post Ohr Pharmaceutical shares plummet after eye drug fails in wet-AMD trial appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply